Cerebrospinal fluid concentrations of vincristine after bolus intravenous dosing

Kellie, Stewart J.; Barbaric, Draga; Koopmans, Pauline; Earl, John; Carr, Deborah; Graaf, Siebold S.N. de

doi:10.1002/cncr.10397

Cited by 60 publications

(29 citation statements)

References 96 publications

(120 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On this basis, we continued to treat GC patients with PC. In most patients we omitted vincristine, since vincristine does not penetrate the blood brain barrier [6]. Here, we present the analysis of 12 patients who had received PC(V) chemotherapy in the pilot phase of a German multicenter trial.…”

Section: Introductionmentioning

confidence: 99%

Procarbazine and CCNU as Initial Treatment in Gliomatosis Cerebri

Glas¹,

Rasch²,

Wiewrodt³

et al. 2008

Oncology

View full text Add to dashboard Cite

Background: Gliomatosis cerebri (GC) is a diffuse infiltrating glial tumor with involvement of at least 3 cerebral lobes. There are only few data on the efficacy of initial chemotherapy in patients with GC. Patients and Methods: In 3 neurooncological centers, patients with newly diagnosed GC who had received procarbazine (60 mg/m², days 8–21/56) and CCNU (110 mg/m², day 1/56) chemotherapy (PC) as initial treatment were analyzed for progression-free survival, overall survival and toxicity. Results: Twelve patients (median age 46 years, range 27–72) were analyzed. The median progression-free survival and the median overall survival were 16 and 37 months. Grade 3 or 4 hematotoxicity was observed in 3 of 12 patients (25%). Conclusions: These data support the efficacy of PC chemotherapy in newly diagnosed GC. Initial PC chemotherapy should be considered as a treatment option and evaluated in larger clinical trials.

show abstract

Section: Introductionmentioning

confidence: 99%

Procarbazine and CCNU as Initial Treatment in Gliomatosis Cerebri

Glas¹,

Rasch²,

Wiewrodt³

et al. 2008

Oncology

View full text Add to dashboard Cite

show abstract

“…Vincristine-induced neurotoxicity is dose-related (Carbone et al, 1963) and causes a peripheral, symmetric mixed sensory-motor, and autonomic polyneuropathy which is more marked distally (Gidding et al, 1999). CNS toxicity from intravenous vincristine is rare, most likely due to poor penetration through the intact blood-brain barrier (Kellie et al, 2002). Corticosteroids may contribute to motor problems in children treated for ALL as they can cause proximal myopathy (DeAngelis et al, 1991).…”

Section: Introductionmentioning

confidence: 99%

Visuomotor control in survivors of childhood acute lymphoblastic leukemia treated with chemotherapy only

Buizer

Sonneville

Heuvel‐Eibrink

et al. 2005

J. Inter. Neuropsych. Soc.

View full text Add to dashboard Cite

Treatment for childhood acute lymphoblastic leukemia (ALL), which includes CNS prophylaxis, is associated with central and peripheral neurotoxicity. The purpose of the present study was to analyze the effects of chemotherapy on various levels of visuomotor control in survivors of childhood ALL treated without cranial irradiation, and to identify risk factors for possible deficits. Visuomotor function was compared between children after treatment for ALL (n 5 34), children after treatment for Wilms tumor, which consists of non-CNS directed chemotherapy (n 5 38), and healthy controls (n 5 151). Three tasks were administered: a simple visual reaction time task and two tasks measuring visuomotor control with one requiring a higher level of cognitive control than the other. Visuomotor deficits were detected only in the ALL group, with poorer performance restricted to the condition requiring the highest level of control. Significant risk factors for poorer performance were female gender and a short time since end of treatment, and a trend was found for a young age at diagnosis. A high cumulative methotrexate dose was an adverse predictive factor in girls. The results indicate that chemotherapy-induced central neurotoxicity in childhood ALL treatment is associated with higher order visuomotor control deficits. Girls appear to be particularly vulnerable. (JINS, 2005, 11, 554-565.)

show abstract

“…All the tumor samples tested against PCV were also exposed to VCR to determine whether the cytotoxic effect of PCV was mainly due to the lipophilic alkylating agents PCB and CCNU or to the high-molecular microtubule inhibitor VCR, which hardly crosses the BBB [28,29]. It turned out that the survival curves after exposure to PCV were indeed very similar to those after VCR alone (Fig.…”

Section: Atp-tcamentioning

confidence: 99%

Can in-vitro chemoresponse assays help find new treatment regimens for malignant gliomas?

Linz¹,

Ulus²,

Neuloh³

et al. 2014

Anti-Cancer Drugs

View full text Add to dashboard Cite

Various in-vitro chemosensitivity and resistance assays (CSRAs) have been demonstrated to be helpful decision aids for non-neurological tumors. Here, we evaluated the performance characteristics of two CSRAs for glioblastoma (GB) cells. The chemoresponse of fresh GB cells from 30 patients was studied in vitro using the ATP tumor chemoresponse assay and the chemotherapy resistance assay (CTR-Test). Both assay platforms provided comparable results. Of seven different chemotherapeutic drugs and drug combinations tested in vitro, treosulfan plus cytarabine (TARA) was the most effective, followed by nimustine (ACNU) plus teniposide (VM26) and temozolomide (TMZ). Whereas ACNU/VM26 and TMZ have proven their clinical value for malignant gliomas in large randomized studies, TARA has not been successful in newly diagnosed gliomas. This seeming discrepancy between in vitro and clinical result might be explained by the pharmacological behavior of treosulfan. Our results show reasonable agreement between two cell-based CSRAs. They appear to confirm the clinical effectiveness of drugs used in GB treatment as long as pharmacological preconditions such as overcoming the blood-brain barrier are properly considered.

show abstract

Cerebrospinal fluid concentrations of vincristine after bolus intravenous dosing

Cited by 60 publications

References 96 publications

Procarbazine and CCNU as Initial Treatment in Gliomatosis Cerebri

Procarbazine and CCNU as Initial Treatment in Gliomatosis Cerebri

Visuomotor control in survivors of childhood acute lymphoblastic leukemia treated with chemotherapy only

Can in-vitro chemoresponse assays help find new treatment regimens for malignant gliomas?

Contact Info

Product

Resources

About